Rafael Holdings Inc. (RFL)
RFL trades on NYSE in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax), fiscal year ended 2026-07-31, https://www.sec.gov/Archives/edgar/data/1713863/000121390026113659/0001213900-26-113659-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2026-07-31.
Profile
| Field | Value |
|---|---|
| Ticker | RFL on NYSE |
| Sector | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Country | United States |
| IPO year | 2018 |
| SEC CIK | 0001713863 |
| SEC industry code | Pharmaceutical Preparations |
| Incorporated in | DE |
Financials · 2026
| Line | Value |
|---|---|
| Revenue | $874K |
| Net income | -$29.6M |
| Operating income | -$33.4M |
| Net margin | -3390.7% |
| Operating margin | -3822.5% |
| Revenue growth | -4.7% |
| Cash | $22.1M |
| Total assets | $83.1M |
| P/E (computed) | Net income was not positive |
| P/S (computed) | 57.9× |
Warning signs
| Sign | Finding | Source |
|---|---|---|
| Going concern | States substantial doubt about continuing as a going concern. "As a result, management has concluded that substantial doubt exists regarding our ability to continue as a going concern for at least 12 months from the date of issuance of the accompanying consolidated financial statements." | 10-K 2026-10-29 |
| Cash and burn | $22.1M cash; operating cash flow -$7.5M a quarter. | Report 2026-07-31 |
| Shares outstanding | 52,184,599 (2026-10-31); 51,770,804 a year earlier. | Cover page 2026-10-31 |
| Reverse splits, 3 years | None found | None on EDGAR |
| Shelf and offerings, 12 months | 0 S-3/F-3 shelf filings; 0 424B5 takedowns | None on EDGAR |
| Exchange deficiency notices, 12 months | None | None on EDGAR |
| Delisting | 25-NSE filed | 25-NSE 2025-12-11 |
| Auditor | CohnReznick LLP, Hartford, Connecticut, United States | PCAOB Form AP 2026-11-11 |
| Late filings, 12 months | None | None on EDGAR |
| Insider trades, 12 months | Bought $0, sold $0 on the open market | SEC Forms 3/4/5 data sets 2026-09-30 |
From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.
Quarterly results
| Quarter | Revenue | Net income | Op. cash flow | Cash | Total debt | TTM revenue | Source |
|---|---|---|---|---|---|---|---|
| Q4 2026 2026-07-31 | Not filed | -$9.2M | -$8.4M | $22.1M | $608K | $874K | 10-K 2026-10-29 |
| Q3 2026 2026-04-30 | $179K | -$4.2M | -$7.3M | $30.5M | $608K | $980K | 10-Q 2026-06-11 |
| Q2 2026 2026-01-31 | $211K | -$6.4M | -$7.5M | $37.8M | $608K | $1.2M | 10-Q 2026-03-16 |
| Q1 2026 2025-10-31 | $240K | -$9.8M | -$6.8M | $45.5M | $608K | $1.0M | 10-Q 2025-12-12 |
| Q4 2025 2025-07-31 | $350K | -$290K | -$10.4M | $52.8M | $2.9M | $917K | 10-K 2025-10-29 |
| Q3 2025 2025-04-30 | $362K | -$4.8M | -$3.2M | $37.9M | $2.3M | $732K | 10-Q 2026-06-11 |
| Q2 2025 2025-01-31 | $77K | -$4.6M | -$2.3M | $48.3M | $4.0M | $706K | 10-Q 2026-03-16 |
| Q1 2025 2024-10-31 | $128K | -$9.0M | -$3.0M | $8.2M | $4.0M | $697K | 10-Q 2025-12-12 |
From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document PROSPECTUS | 424B3 | 2025-05-06 |
| Latest annual report ANNUAL REPORT | 10-K | 2026-10-29 |
| Latest quarterly / interim QUARTERLY REPORT | 10-Q | 2026-06-11 |
| Latest current report CURRENT REPORT | 8-K | 2026-11-09 |
| Latest proxy PROXY STATEMENT | DEF 14A | 2026-11-16 |
Source: SEC EDGAR submissions feed, 411 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | +2.9% |
| 1 month | -28.2% |
| 3 months | -45.7% |
| Year to date | -9.3% |
| 1 year | -15.1% |
| From 52-week high | -71.7% |
Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Biotechnology: Pharmaceutical Preparations
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| QUCY | Quantum Cyber N.V. | $0.5850 | -7.58% | $51.0M |
| IBIO | iBio Inc. | $0.7067 | -3.42% | $49.8M |
| CTOR | Citius Oncology Inc. | $0.5350 | -6.76% | $49.7M |
| SDEV | Stablecoin Development Corporation | $0.7055 | -9.55% | $51.6M |
| APLM | Apollomics Inc. | $17.84 | +0.91% | $51.7M |
| MREO | Mereo BioPharma Group plc | $0.3050 | -0.81% | $48.7M |
| CLNN | Clene Inc. | $3.66 | -6.63% | $52.7M |
| HOWL | Werewolf Therapeutics Inc. | $0.9908 | +1.07% | $48.2M |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier